You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

ibrutinib

Showing 51 - 75 of 220
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma Trial in United States (Ublituximab, Ibrutinib)

Completed
  • Chronic Lymphocytic Leukemia
  • Mantle Cell Lymphoma
  • Huntsville, Alabama
  • +17 more
Oct 21, 2022

Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma Trial in United States (Abexinostat, Ibrutinib)

Active, not recruiting
  • Diffuse Large B-cell Lymphoma
  • Mantle Cell Lymphoma
  • Basking Ridge, New Jersey
  • +6 more
Aug 11, 2022

Primary Diffuse Large B-cell Lymphoma of the CNS (CNS), Aggressive B-cell Lymphoma With Secondary Involvement of the CNS Trial

Suspended
  • Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS)
  • Aggressive B-cell Lymphoma With Secondary Involvement of the CNS
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jul 6, 2022

Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia Trial in

Active, not recruiting
  • Stage I Chronic Lymphocytic Leukemia
  • +3 more
  • Ibrutinib
  • Laboratory Biomarker Analysis
  • Jacksonville, Florida
    Mayo Clinic in Florida
Mar 24, 2022

Metastatic Renal Cell Cancer, Stage IV Renal Cell Cancer Trial in Sacramento (Ibrutinib, Nivolumab)

Completed
Has Results
  • Metastatic Renal Cell Cancer
  • Stage IV Renal Cell Cancer
  • Sacramento, California
    University of California Davis Comprehensive Cancer Center
Feb 8, 2022

Chronic Lymphocytic Leukemia, Leukemia Trial in United States (Ibrutinib, Fludarabine, Cyclophosphamide)

Active, not recruiting
Has Results
  • Chronic Lymphocytic Leukemia
  • Leukemia
  • Ibrutinib
  • +3 more
  • Coral Gables, Florida
  • +8 more
Sep 28, 2022

Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Recurrent Small

Recruiting
  • Recurrent Chronic Lymphocytic Leukemia
  • +4 more
  • Daratumumab
  • Ibrutinib
  • Jacksonville, Florida
    Mayo Clinic in Florida
Mar 22, 2022

Refractory/Recurrent Primary CNS Lymphoma (PCNSL) Trial in United States (Ibrutinib, Copanlisib)

Recruiting
  • Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL)
  • Basking Ridge, New Jersey
  • +6 more
Jul 27, 2022

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma Trial in United States (TGR-1202, Ibrutinib)

Active, not recruiting
Has Results
  • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  • Mantle Cell Lymphoma
  • Monterey, California
  • +4 more
Aug 29, 2022

Chronic Lymphocytic Leukemia, Loss of Chromosome 17p Trial (Ibrutinib, Venetoclax)

Withdrawn
  • Chronic Lymphocytic Leukemia
  • Loss of Chromosome 17p
  • (no location specified)
Oct 29, 2021

Primary CNS Lymphoma, PCNSL, Non Hodgkin Lymphoma Trial in Guandong, Guangzhou (Methotrexate, Ibrutinib, Temozolomide)

Recruiting
  • Primary Central Nervous System Lymphoma
  • +2 more
  • Guandong, Guangdong, China
  • +2 more
Apr 6, 2022

Waldenstrom Macroglobulinemia, Waldenstrom's Disease, Waldenström; Hypergammaglobulinemia Trial in New York (Ibrutinib,

Recruiting
  • Waldenstrom Macroglobulinemia
  • +6 more
  • New York, New York
    Weill Cornell Medicine
Dec 21, 2021

Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma Trial in Palo Alto (Ibrutinib, Radiation

Active, not recruiting
  • Grade 1 Follicular Lymphoma
  • +6 more
  • Ibrutinib
  • +2 more
  • Palo Alto, California
    Stanford University, School of Medicine
Jun 13, 2022

Blastoid Variant Mantle Cell Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Follicular Lymphoma Trial in United

Active, not recruiting
  • Blastoid Variant Mantle Cell Lymphoma
  • +8 more
  • Ibrutinib
  • Laboratory Biomarker Analysis
  • Birmingham, Alabama
  • +4 more
May 10, 2022

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Houston (Cyclophosphamide, Fludarabine Phosphate, Ibrutinib)

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
Aug 18, 2022

Mantle Cell Lymphoma Trial in Hackensack (Lenalidomide, Ibrutinib, Rituximab)

Active, not recruiting
  • Mantle Cell Lymphoma
  • Hackensack, New Jersey
    The Cancer Center at Hackensack University Medical Center
May 3, 2022

Primary Central Nervous Lymphoma, Intraocular Lymphoma Trial in France (Ibrutinib)

Completed
  • Primary Central Nervous Lymphoma
  • Intraocular Lymphoma
  • Ibrutinib
  • Clermont Ferrand, France
  • +9 more
Apr 6, 2022

Lymphoma, Large B-Cell, Diffuse, CNS Tumors, Primary Trial in France (Lenalidomide, Ibrutinib)

Recruiting
  • Lymphoma, Large B-Cell, Diffuse
  • Central Nervous System Neoplasms, Primary
  • Amiens, France
  • +26 more
Nov 30, 2022

Loss of Chromosome 17p, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma Trial in Houston (drug,

Completed
  • Loss of Chromosome 17p
  • +5 more
  • Ibrutinib
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Mar 4, 2022

Chronic Lymphocytic Leukemia Trial in Cologne (Ibrutinib, Placebo)

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Ibrutinib
  • Placebo
  • Cologne, Germany
    German CLL Study Group
Dec 16, 2021

Aplastic Anemia, Hematopoietic and Lymphoid Cell Tumor, Malignant Solid Tumor Trial in Columbus (Best Practice, Ibrutinib)

Active, not recruiting
  • Aplastic Anemia
  • +6 more
  • Best Practice
  • Ibrutinib
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Feb 24, 2022

Leukemia, T-cell Prolymphocytic Leukemia (T-PLL), Cancer Trial in Worldwide (Venetoclax, Ibrutinib)

Completed
Has Results
  • Leukemia
  • +2 more
  • Boston, Massachusetts
  • +14 more
Nov 23, 2022

Mantle Cell Lymphoma Trial in Germany, Italy, Switzerland (Ibrutinib, bortezomib)

Terminated
  • Mantle Cell Lymphoma
  • Mainz, Germany
  • +18 more
Feb 24, 2022

Chronic Lymphocytic Leukemia Trial in Boston, Rochester, Durham (Obinutuzumab, Ibrutinib)

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Boston, Massachusetts
  • +3 more
Jan 3, 2022

Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma Trial in Portland (Ibrutinib, Obinutuzumab)

Completed
Has Results
  • Recurrent Mantle Cell Lymphoma
  • Refractory Mantle Cell Lymphoma
  • Ibrutinib
  • Obinutuzumab
  • Portland, Oregon
    OHSU Knight Cancer Institute
Dec 10, 2021